Hikma Pharmaceuticals intends in the near future to expand its European Injectables business into France and Spain, thereby ensuring a presence in Europe’s ‘big five’ markets through its existing presence in Germany, Italy and the UK. Furthermore, aided by enhanced manufacturing capacity, the company is assessing options to leverage its European and US injectables portfolio and pipeline by setting up a sales and marketing function in Canada.
Speaking exclusively to Generics Bulletin, the president of Hikma’s Injectables division, Riad Mishlawi acknowledged that Hikma’s presence in the European...




